Rotateq Oral Vaccine 2ml Injection

The Rotateq Oral Vaccine is a live, oral, pentavalent rotavirus vaccine designed for the prevention of rotavirus gastroenteritis in infants and children [16, 38, 41]. This vaccine is indicated for infants between 6 to 32 weeks of age to protect against gastroenteritis caused by rotavirus types G1, G2, G3, G4, and G9 [1, 2, 3, 15, 17, 18, 23, 35, 41]. It is administered as a 2ml oral solution and is not for injection [7, 10, 11, 12, 13, 22, 33, 35, 41].

The vaccination series consists of three ready-to-use liquid doses [3, 12, 13, 15, 18]. The first dose should be given between 6 and 12 weeks of age, with subsequent doses administered at 4- to 10-week intervals [1, 3, 11, 12, 13, 15, 17, 18, 22, 30]. The third dose should not be given after 32 weeks of age [1, 3, 11, 12, 13, 15, 18, 30].

Key Features : 

Antigen Composition: Contains five live human-bovine reassortant rotavirus strains (G1, G2, G3, G4, and G9) [2, 6, 9, 16, 17, 21, 23, 32, 34, 35, 38, 41].
Approved Indications and Target Population: Prevents rotavirus gastroenteritis in infants and children aged 6 to 32 weeks [1, 2, 3, 15, 17, 18, 23, 35, 41].
Cold-chain Storage: Requires refrigeration at 2-8°C (36-46°F) and protection from light [1, 7, 11, 14, 15, 20, 24, 26, 27].
Route of Administration: Administered orally; not for injection [3, 7, 10, 11, 12, 13, 22, 33, 35, 41].
Schedule / Dosing Intervals: A 3-dose oral regimen, with the first dose between 6-12 weeks of age and subsequent doses at 4-10 week intervals, completed by 32 weeks of age [1, 3, 11, 12, 13, 15, 17, 18, 22, 30].
Regulatory Approval: Approved by the FDA in 2006 and WHO Prequalified since October 2008 [2, 4, 5, 6, 8, 10, 22, 26, 27, 31, 32].
Reconstitution Requirements: Supplied as a ready-to-use liquid solution, requiring no reconstitution [3, 5, 7, 11, 21, 27, 29, 39, 40].